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Background. Neisseria meningitidis (Nm) is a nasopharyngeal commensal carried by healthy individuals. However, invasive 
infections occurs in a minority of individuals, with devastating consequences. There is evidence that common polymorphisms are 
associated with invasive meningococcal disease (IMD), but the contributions of rare variants other than those in the complement 
system have not been determined.
Methods. We identified familial cases of IMD in the UK meningococcal disease study and the European Union Life-Threatening 
Infectious Disease Study. Candidate genetic variants were identified by whole-exome sequencing of 2 patients with familial IMD. 
Candidate variants were further validated by in vitro assays.
Results. Exomes of 2 siblings with IMD identified a novel heterozygous missense mutation in BPIFA1/SPLUNC1. Sequencing 
of 186 other nonfamilial cases identified another unrelated IMD patient with the same mutation. SPLUNC1 is an innate immune 
defense protein expressed in the nasopharyngeal epithelia; however, its role in invasive infections is unknown. In vitro assays dem-
onstrated that recombinant SPLUNC1 protein inhibits biofilm formation by Nm, and impedes Nm adhesion and invasion of human 
airway cells. The dominant negative mutant recombinant SPLUNC1 (p.G22E) showed reduced antibiofilm activity, increased menin-
gococcal adhesion, and increased invasion of cells, compared with wild-type SPLUNC1.
Conclusions. A mutation in SPLUNC1 affecting mucosal attachment, biofilm formation, and invasion of mucosal epithelial cells 
is a new genetic cause of meningococcal disease.
Keywords.  severe infectious disease; meningococcal disease; mucosal immunity; human genetics; sepsis.
Neisseria meningitidis (Nm) colonizes the epithelia of the na-
sopharynx in the upper respiratory tract in a high proportion 
of healthy children and adults intermittently throughout life. In 
Europe and the United States, carriage rates range from 10–30% 
[1], although the majority of individuals colonized by the bac-
teria do not develop invasive disease and remain asymptomatic. 
In less than 1% of carriers, the bacteria infiltrate the epithelial 
barrier and enter the bloodstream, causing life-threatening 
sepsis and/or meningitis [2], often with devastating conse-
quences. The incidence rates of invasive meningococcal disease 
(IMD) in the prevaccine era were 5–10 cases per 100 000 chil-
dren per year in Europe and North America [3]. Although an-
tibiotic treatment is highly effective, the mortality rate remains 
between 8–14% [4]. In addition, a significant proportion of sur-
vivors have long-term sequelae, including hearing loss, other 
neurological deficits, skin scarring, or amputation [5].
The critical role of bactericidal antibodies in protection 
against IMD is well documented [6, 7]. Furthermore, innate 
immune effectors—in particular, in the complement system—
are also essential in controlling Nm replication. Pathogen 
recognition receptors, such as toll-like receptor  (TLR)4 and 
TLR2, which bind Nm lipopolysaccharide (LPS) and porin B, 
activate NF-kB, leading to pro-inflammatory cytokine pro-
duction [8]. Epithelial cells in the upper airway produce sev-
eral antimicrobial peptides and surfactant proteins to combat 
Nm infection, including cathelicidin LL-37 and surfactant 
proteins -A and -D [9, 10].
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Genetic variants affecting components of the host immune 
response have been shown to underlie IMD [11]. Increased sib-
ling risk ratios, λ s, in children with IMD have been reported, 
implicating host genetics in disease susceptibility [12]. A large 
multi-country genome wide association study complement 
factor H established that polymorphisms in the CFH region 
were associated with susceptibility to IMD [13, 14]. Candidate 
gene studies have implicated a number of other genes in ei-
ther susceptibility to or severity of disease, including the in-
terleukin 1 gene cluster, comprising IL1RN and IL1β [15, 16], 
and an insertion deletion in the coagulation gene SERPINE1 
[17]. Monogenic disorders of the central complement ele-
ment C3, the alternative pathway (factor D, properdin, factor 
H, and factor I), and terminal components of the complement 
system (C5–C9) have been well documented to confer selec-
tive susceptiblity to IMD [18–22]. Additionally, patients with 
mutations in genes involved in signal transduction downstream 
of TLRs, autosomal recessive (AR) interleukin-1 receptor-
associated kinase 4 (IRAK4) [23], and AR NF-kappa-B essential 
modulator (NEMO) deficiencies [24], usually linked to inva-
sive pneumococcal infections, have been described as suffering 
from IMD. Rare variants in F5 and TLR4 have also been impli-
cated in severity and susceptibility to disease [25, 26].
Although the studies described above provide evidence of a 
strong genetic contribution to IMD susceptibility, the genes iden-
tified to date explain only a small proportion of IMD patients. In 
an effort to uncover new genetic aetiologies of IMD, we employed 
whole-exome sequencing (WES) of well-defined familial cases 
that led to the identification of a novel mutation in SPLUNC1. 
This gene encodes for the secreted BPIFA1/SPLUNC1 (25 kDa) 
protein, expressed in the upper respiratory tract. SPLUNC1 has 
been studied in the context of respiratory infections and inferred 
to prevent infections by inhibiting bacterial biofilm formation 
[27–31]. Given that this secreted protein with surfactant prop-
erties is highly expressed in the nasopharyngeal epithelial tissues 
[32, 33], a site of Nm colonization, and that polymorphisms in 
SPLUNC1 have been associated with impaired airway functions 
[34–36], we hypothesized that the implicated genetic modifica-
tion may confer increased susceptibility to IMD.
MATERIALS AND METHODS
Study Cohorts
The UK meningococcal disease cohort included participants 
diagnosed with meningococcal disease and enrolled through 
several recruitment sites, including St Mary’s Hospital London, 
the Meningitis Research Foundation, and Alder Hey Children’s 
Hospital in Liverpool. Complete clinical details of the partici-
pants have been previously described elsewhere [13].
The European Union Childhood Life-Threatening Infectious 
Disease Study (EUCLIDS) included febrile children presenting 
to hospital with a suspected bacterial infection [37]. A total of 
549 patients with invasive bacterial infections were selected for 
WES, of which 220 were diagnosed with meningococcal disease. 
Meningococcal disease was diagnosed in persons presenting with 
petechial or purpuric rash and meningitis and/or septicaemia. 
Confirmation of the disease was made by a bacterial culture or 
polymerase chain reaction from blood or cerebrospinal fluid.
Nasal fluid samples were collected from healthy infants under 
ethical approval from the Black Country Research Ethics com-
mittee (reference 15/WM/0343).
Nasal Fluid Collection
Nasal fluids were collected using Nasosorption FXi-13 devices 
(Mucosal Diagnostics UK, Ltd.), which were manipulated into 
the nostril lumen and depressed for 30 seconds. Samples were 
then eluted from Nasosorption devices in phosphate-buffered 
saline (PBS) with 1% BSA and 0.05% Tween-20. Subsequently, 
SPLUNC1 expression was detected in these samples using 
standard Western blotting with a goat antihuman SPLUNC1 
primary antibody (R&D Systems, Cat# AF1897) and rabbit 
antigoat horseradish peroxidase-conjugated detection (Cat# 
SC2768) antibody. As a method to control for sample loading, 
human serum albumin expression was determined simultane-
ously with the use of a DuoSet enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems Cat# DY1455), following the 
manufacturer’s recommendation.
Whole-exome Sequencing and Variant Annotation
The patients’ genomic DNA samples were extracted using a 
standard laboratory technique and subjected to genomic DNA 
library preparation and capture at Oxford Gene Technology 
(Oxfordshire, United Kingdom). Protein-coding regions were 
targeted using Agilent’s SureSelect Human All Exon v4 platform. 
The enriched libraries were sequenced on Illumina HiSeq 2000, 
achieving an average target coverage of ~44 x across samples, 
with 85% of exonic bases sequenced at least 10x. The resulting 
paired-end 100 base pair–long sequencing reads were aligned to 
the human genome (assembly version GRCh37) using bwa v0.7 
[38]. De-duplication and sequencing quality assessment were 
performed using the Picard tools (http://broadinstitute.github.
io/picard), followed by joint sample genotyping with genome 
analysis tool kit [39]. The resulting single nucleotide polymor-
phism (SNP) and indel variant calls were functionally anno-
tated using Ensembl’s Variant Effect Predictor [40]. Finally, to 
leverage familial relationships in our samples, we developed an 
algorithm that prioritized variants that appeared to be identical 
by descent in the individuals of interest.
Expression and Purification of Human SPLUNC1
We performed recombinant SPLUNC1 (rSPLUNC1) protein 
mutagenesis, expression, and purification as previously de-
scribed [41, 42]. Briefly, the G22E and N-terminal deleted (ΔN) 
mutant constructs were created from the full-length SPLUNC1 
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cDNA using polymerase chain reaction mutagenesis. Wild-type 
(WT) and mutated SPLUNC1 cDNAs were cloned into pMCSG7 
for protein expression. BL21-CodonPlus competent cells were 
transformed with the expression plasmid and grown in Luria-
Bertani (LB) broth supplemented with an antibiotic cocktail to 
reach an optical density (OD600) of 0.6. Expression was induced 
by adding 0.1  mM of isopropyl-1-thio-D-galactopyranoside. 
The soluble fraction was purified using an Ni-NTA His-trap 
gravity column and analyzed with a S200 gel filtration column 
on an ÄKTAxpress (GE Healthcare).
Neisseria meningitidis Growth Assay in the Presence of Recombinant 
SPLUNC1
The bactericidal activity of SPLUNC1 was tested by incubating 
the WT MC58 Nm strain with varying concentrations of human 
rSPLUNC1. Nm were grown on brain heart infusion (BHI) 
agar at 37°C in 5% CO2 overnight. The next day, bacteria were 
subcultured in BHI broth to reach mid-log phage growth and 
the culture was adjusted to an OD600 of 0.1 (10
8 colony forming 
unit [CFU] per mL). For individual experiments, approximately 
106 cells were incubated alone or in the presence of increasing 
amounts of rSPLUNC1 (1 µg, 5 µg, and 10 µg) or the control 
protein, BSA. At time points from 0–24 hours, aliquots were 
collected and plated out on BHI agar to determine the viable 
counts of surviving bacteria.
Neisseria meningitidis Adhesion and Invasion Assays
Human bronchial epithelial cell line (16HBE14) cells were grown 
in Dulbecco’s Modified Eagle Medium (DMEM), supplemented 
with 10% fetal bovine serum at 37°C in 5% CO2. Nm cells grown 
on BHI agar plates were suspended in PBS to achieve an multi-
plicity of infection of 1 for both adherence and invasion assays, 
as previously described [43]. Briefly, the confluent monolayer of 
epithelial cells was infected with Nm in the presence or absence 
of rSPLUNC1 or BSA (10 µg per ml). For the adherence assay, 
after 4 hours, wells were washed 3 times with PBS and incu-
bated with 1% saponin for 10 minutes at 37°C. For the invasion 
assay, gentamicin (Sigma) was added to each well at a final con-
centration of 150 µg/ml and incubated for 1 hour at 37°C. Wells 
were washed 3 times with PBS and subsequently incubated with 
saponin as above, and viable counts were determined by CFU 
counting. Data are presented as the percentage of CFUs, com-
pared to infecting inoculum. Each condition tested was carried 
out in triplicate at least 3 independent times.
Lipopolysaccharide Binding Assay
A slightly modified version of the ELISA-based LPS binding 
test was used to measure the LPS binding abilities of SPLUNC1 
variants. Briefly, a 96-well plate was coated with purified LPS 
(250 ng) from Nm serogroup B (courtesy of Peter Van Der Ley, 
Institute for Translational Vaccinology, Intravacc) or Salmonella 
Minnesota R595 (InvivoGen) overnight. The rest of the steps 
were performed as per protocol [44]. Absorbance readings were 
analyzed using SoftMax Pro software (Molecular Devices). The 
results are based on at least 3 independent experiments and rep-
resented as means ± standard errors of the mean.
Biofilm Biomass Assay
A modified version of a previously described microtiter assay was 
used to assess the meningococcal surface attachment to an abiotic 
surface. Briefly, WT and pili deficient ( pilE-) MC58 strains were 
suspended in DMEM to obtain the OD600 of 0.5 from the over-
night growth from supplemented BHI plates. Assay wells were 
incubated with SPLUNC1 protein or BSA for 3 hours at 37°C. 
Wells containing bacteria inoculated without the addition of re-
combinant protein were also used as controls. Biofilm-forming 
microcolonies were stained for 15 minutes using 0.5% aqueous 
crystal violet; were washed twice in water to remove excess stain; 
had 80% ethanol added; and had ODs measured at 590 nm.
Statistical Analysis
We assessed differences between controls and SPLUNC1 pro-
teins in bacterial growth, biofilm, and adhesion or invasion 
assays using 1- or 2-way analyses of variance, followed by a 
Tukey’s multiple comparison test or Student’s t-test. Unless oth-
erwise stated, a P <  .05 was considered statistically significant 
for all analyses.
RESULTS
Whole-exome Sequencing of Familial Invasive Meningococcal Disease 
Cases 
Children with confirmed IMD, sepsis, and/or meningitis were 
recruited through the UK meningococcal disease study [13] and 
the EUCLIDS [37]. We performed WES on multiplex families 
with confirmed diagnoses of IMD. We focused on a family (kin-
dred A) with 2 siblings who suffered from meningococcal sepsis, 
with incidences occurring 5  years apart (see Supplementary 
Table 1). They were both found to have normal, functional, 
complement-mediated killing of Nm [45] and specific bacteri-
cidal antibodies. Clinical investigations excluded complement 
or antibody deficiencies (see Supplementary Figure 1). Due to 
its breadth of coverage, WES identified multiple candidate vari-
ants that appeared to have been shared by the siblings. However, 
many of these variants needed to be excluded, as they were in-
herited from a different parent in each of the siblings and were, 
thus, only identical by state and not by descent [46, 47]. Since the 
parent DNA was not available, we could not perform pedigree-
based phasing to directly determine identity by descent (IBD) 
in our siblings. Instead, we undertook population-based phasing 
using SHAPEIT [48], and then cross-referenced the resulting 
haplotype blocks to obtain IBD genomic segments. This allowed 
us to adopt a modified familial filtering approach that began by 
excluding variants falling outside IBD blocks. Within the shared 
segments, we limited our search to novel or rare sequence vari-
ants (<1% minor allele frequency). Variants were annotated 
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using Ensembl’s Variant Effect Predictor [40], excluding syn-
onymous variants and those that were predicted to have a low 
impact on the resulting protein. Using this filtration, we iden-
tified 231 variants in the siblings (see Supplementary Table 2). 
To narrow down the candidate variants, Combined Annotation 
Dependent Depletion (https://cadd.gs.washington.edu/) and 
bidirectional Sorting Intolerant from Tolerant [49] scores were 
calculated, highlighting those variants that were likely to impact 
on function. The prioritizing of genes, using the gene damage 
index, was also incorporated into the analyses. No mutations 
consistent with any of the known genetic aetiologies underlying 
the known primary immunodeficiencies were identified [50] 
(see Supplementary Table 2). We prioritized SPLUNC1—also 
known as BPIFA1, and which harbored a novel mutation—as a 
candidate, due to its known role in host defense against Gram-
negative bacteria [27, 44].
SPLUNC1 is a secreted protein expressed exclusively in the 
nasopharyngeal tract, with proportionately higher expres-
sion in the nasal lining fluid of children compared with adults 
(Supplemental Figure 4B).The novel SPLUNC1 missense muta-
tion changes a guanine to an alanine residue at nucleotide posi-
tion 65, leading to glutamic acid in place of a glycine at amino 
acid position 22 (Figure 1A). Further targeted sequencing of 
186 IMD patients from the UK meningococcal disease study 
[13] revealed an unrelated case (P3; kindred B) who also car-
ried the same heterozygous SPLUNC1 mutation (Figure 1A and 
1B; see Supplementary Table 2). Sanger sequencing in all 3 pa-
tients subsequently confirmed the variant. WES of P3 revealed 
no variants corresponding to any known primary immuno-
deficiencies. This SPLUNC1 (c.65G  >  A, p.G22E) variant was 
absent from known public databases (dbSNP, EVS, gnomAD, 
and Bravo 1k Genomes) and from our in-house database, which 
comprises 549 exomes of children with life-threatening infec-
tions (Figure 1B). The p.G22E mutation affects the N-terminus 
of the SPLUNC1 protein (Figure 1C), which is unique from 
the other bactericidal permeability increasing family protein 
sequences and has been shown to regulate epithelial sodium 
transport, influencing mucociliary clearance in the host airway 
[41]. Moreover, the glycine residue is well conserved across pri-
mates and differs from other species (Figure 1D), reflective of 
the diversity in function and pH dependency of the N-terminal 
domain of the protein along the evolutionary tree [41].
Recombinant SPLUNC1 Inhibits Neisseria meningitidis Biofilm Formation
The rSPLUNC1 protein was previously shown to exert surface 
tension–reducing properties in airway secretions, consistent 
with its surfactant-like properties, which are responsible for 
the inhibition of biofilm formation by various pathogens in the 
airway [27, 29, 51, 52]. We assessed this surfactant property 
of SPLUNC1 in the context of Nm biofilm formation using a 
standard microtitre plate–based bacterial biofilm assay [53]. 
Biofilm formation was measured on the surface of a microtitre 
plate in the presence of BSA, WT, or mutant G22E rSPLUNC1 
proteins (Figure 2). The SPLUNC1 protein constructs were gen-
erated using mutagenesis, and protein expression and purifica-
tion were performed using previously described methods [42]. 
The Nm MC58 pilE- strain was included as a control, as it is im-
paired in its ability to form biofilm, compared with its isogenic 
parent Nm MC58 WT [54]. Since the G22E mutation is located 
in the N-terminus, we also used a mutant protein containing a 
Figure 1. A heterozygous missense BPIFA1/SPLUNC1 mutation identified in invasive meningococcal disease (IMD) patients. A novel missense c.65 G > A, p.G22E SPLUNC1 
mutation was found in 3 IMD patients in 2 kindreds. A, Pedigrees of the 2 families’ affected individuals are shaded in black and probands are indicated by arrows. B, SPLUNC1 
sequencing from control and patients. Arrow indicates the position of the mutation. C, Schematic representation of the SPLUNC1 protein, with the signal peptide domain 
(SP) and BPI–alpha/beta homologous domain (BPI-α/β) indicated.) D, Amino acid sequence alignment showing conservation of the N-terminal domain of SPLUNC1 across 
different species. Abbreviation: COOH, C-terminal domain of proteins; IMD, invasive meningococcal disease LPS, lipopolysaccharide; WT, wild-type.
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deletion of its entire N-terminal domain (ΔN rSPLUNC1; amino 
acids 1–44) [41]. The presence of the WT rSPLUNC1 protein 
significantly reduced (P < .0001) the biofilm formation of Nm, 
compared with BSA (Figure 2; see Supplementary Figure  2). 
Both mutant p.G22E and ΔN rSPLUNC1 proteins elicited an 
impaired capacity to inhibit biofilm formation of Nm. No signif-
icant difference in biofilm formation was observed with any of 
the proteins by the isogenic pilE- mutant, which lacks the natural 
ability to form biofilm on a polystyrene surface [54].
Recombinant SPLUNC1 has no Bactericidal Effect on Neisseria 
meningitidis Growth
SPLUNC1 has been reported to elicit bacteriostatic proper-
ties against a number of Gram-negative bacteria, including 
Pseudomonas aeruginosa [30] and Burkholderia cenocepacia 
[42]. In order to investigate whether rSPLUNC1 has any di-
rect bactericidal effect on Nm growth, a bacterial viability 
assay was performed in the presence of WT rSPLUNC1. Our 
results showed that rSPLUNC1 did not elicit bactericidal ac-
tivity on Nm growth under the conditions tested (Figure 3A; 
see Supplementary Figure 3). We did not detect a difference in 
bacterial growth in the presence of rSPLUNC1 or BSA during 
the 3-hour incubation period. Similar results were found when 
bacterial viability was assessed over 24 hours (Figure 3B).
Recombinant SPLUNC1 Inhibits Neisseria meningitidis Adhesion and 
Invasion 
The nasopharyngeal acquisition of Nm via close contact with 
saliva or respiratory droplets can lead to prolonged colonization 
of the nasopharynx or lead to invasive disease [1]. Patient cells 
were unavailable, so a human airway cell line was used to carry 
out molecular investigations of this protein. To assess whether 
SPLUNC1 is involved in early events of invasive infection by 
Nm, we compared adherence and invasion of Nm in 16HBE14 
in the presence of WT or mutant G22E rSPLUNC1 proteins. 
An immunoblotting analysis from whole-cell lysates con-
firmed that 16HBE14 do not express endogenous SPLUNC1 
(Supplementary Figure 4A). The presence of WT rSPLUNC1 
significantly inhibited Nm adherence to 16HBE14 cells 
(6.8%; P  <  .0001), compared with BSA (89.67%; Figure 4A; 
see Supplementary Figure 5). Both the G22E and ΔN mutant 
rSPLUNC1 proteins elicited a reduced ability to inhibit adher-
ence to 16HBE14 cells by Nm, giving an adherence capacity 
of 26.2% and 16.3%, respectively, and suggesting an impaired 
rSPLUNC1 function. Consistent with its effect on adherence, 
the WT rSPLUNC1 also elicited significant inhibition (0.044%; 
P =  .01) on bacterial invasion into 16HEB14 cells (Figure 4B) 
Figure 2. Nm biofilm formation is inhibited by rSPLUNC1. Biofilm biomass formed 
by WT or pilE-mutant Nm in media supplemented with BSA, WT, mutant G22E, or 
ΔN mutant rSPLUNC1 proteins are shown on a microtitre plate. Results are ex-
pressed as the means  ±  SEMs from 3 independent experiments. Statistical sig-
nificance was assessed using a 2-way ANOVA, followed by Tukey’s test. *P < .05; 
**P <  .001. Abbreviations: ΔN, N-terminal deleted; ANOVA, analysis of variance; 
Nm, Neisseria meningitidis; OD, optical density; pilE, pili deficient; rSPLUNC1, re-
combinant SPLUNC1; SEM, standard error of the mean; WT, wild-type. 
Figure 3. Nm growth is not affected by rSPLUNC1. Nm was grown in the pres-
ence of WT rSPLUNC1 or BSA for up to (A) 3 hours or (B) 24 hours. The bacterial vi-
ability was assessed by counting CFUs at regular intervals during infection. Results 
are expressed as means ± SDs from at least 3 independent experiments carried 
out in triplicates. Statistical significance was assessed using the Student’s t-test. 
Abbreviations: Nm, Neisseria meningitidis; rSPLUNC1, recombinant SPLUNC1; SD, 
standard deviation; WT, wild-type.
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with respect to BSA (0.097%). Neither mutant rSPLUNC1 pro-
tein showed any inhibitory effect on invasion.
Mutant G22E Recombinant SPLUNC1 Protein Exerts a Dominant-negative 
Effect 
We investigated the molecular mechanisms by which the patients’ 
heterozygous G22E mutation may exert its deleterious effects. We 
showed that WT rSPLUNC1 is capable of inhibiting adherence 
and invasion of 16HBE14 cells by Nm at physiologically relevant 
concentrations [51], whereas the G22E mutant showed attenua-
tion of the rSPLUNC1 function. Thus, we next assessed the effect 
of the mutant G22E protein on the WT protein function by treating 
cells with equal amounts of WT and G22E mutant rSPLUNC1 
using the bacterial adherence assay. We observed similar levels of 
inhibition on adherence to 16HBE14 cells by Nm in the presence 
of 10 and 15 µg/ml of WT rSPLUNC1 (see Supplementary Figure 
6). From this, we inferred that the rSPLUNC1 protein operates 
at a minimal effective dose of 10 µg/ml. We observed less inhi-
bition at 220 vs 10ug/ml of WT rSPLUNC1 (26.8% vs 35.8%), 
although this was still significantly different from all doses tested 
using mutant G22E rSPLUNC1 (43.5% and 45.8%; Figure 5; see 
Supplementary Figure 6). We used the minimal effective dose of 
WT rSPLUNC1 (10 µg/ml) as the baseline to test any inhibitory 
effect of the mutant G22E protein. We found that the addition of 
mutant G22E to WT rSPLUNC1 led to the attenuation of the WT 
SPLUNC1 function, from 27.3% to 49.0% adherence, resulting in 
a similar level of bacterial adherence to the G22E mutant alone 
(45.0%; Figure 5).
Mutant G22E Recombinant SPLUNC1 is Able to Bind Lipopolysaccharide
Several studies have demonstrated that SPLUNC1 shares ho-
mology with host immune defense neutrophil proteins, such as 
BPI, and thus retains the ability to bind directly to bacterial LPS 
[44]. ELISA-based LPS-binding assays were used to evaluate 
SPLUNC1’s ability to bind LPS produced by Gram-negative 
bacteria such as Nm. LPS is recognized by human cells ex-
pressing TLR4, upon which a cascade of host immune defense 
mechanisms are initiated [55]. We used Nm LPS from the IgtB 
Figure 5. The mutant G22E rSPLUNC1 protein is dominant negative. Bacterial 
adherence to 16HBE14 was tested in the presence of increasing doses of mu-
tant G22E and/or WT rSPLUNC1. The amounts of recombinant protein used are 
displayed below the bar. The adherent bacteria were determined by CFU counts. 
Each condition was carried out in triplicate and the means ± SEMs from 5 inde-
pendent experiments, following 4 hours adherence, are shown. *P < .05, **P < .001: 
determined by 1-way ANOVA with Tukey’s test. Abbreviations: 16HBE14, human 
bronchial epithelial cell line; ANOVA, analysis of variance; rSPLUNC1, recombinant 
SPLUNC1; SEM, standard error of the mean; WT, wild-type.
Figure 4. Nm adherence and invasion of 16HBE14 is inhibited by rSPLUNC1. 
The effects of BSA, WT, mutant G22E, or ΔN mutant rSPLUNC1 proteins on (A) 
Nm adherence or (B) invasion into 16HBE14 cells were assessed. Each condition 
was carried out in triplicate and the means ± SEMs from 3 independent experi-
ments, following 4 hours incubation, are shown. *P < .05, **P < .001: determined by 
1-way ANOVA with Tukey’s test. Abbreviations: ΔN, N-terminal deleted; 16HBE14, 
human bronchial epithelial cell line; ANOVA, analysis of variance; Nm, Neisseria 
meningitidis; rSPLUNC1, recombinant SPLUNC1; SEM, standard error of the mean; 
WT, wild-type.
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mutant, which lacks the terminal galactose residue but is not 
known to impact binding to surface proteins [56]. WT and mu-
tant rSPLUNC1 bound equally well to Nm LPS (Figure 6), as 
well as to LPS derived from another Gram-negative bacterium: 
Salmonella enterica var Minnesota.
DISCUSSION
We undertook WES of a cohort of patients with IMD and iden-
tified 3 meningococcal patients from 2 families with a novel mu-
tation in SPLUNC1. The encoding protein, SPLUNC1, is secreted 
by airway epithelial cells and its expression has been shown to 
be highly modulated during bacterial or viral infections [31, 44, 
51, 52]. Previous studies have demonstrated that SPLUNC1 is an 
innate immune defense protein with antimicrobial activity that 
can impede bacterial growth by modifying biofilm formation 
and has bacteriostatic activity against Gram-negative bacteria, 
including P. aeruginosa [27, 30]. Given the role of biofilms in me-
ningococcal infections [57, 58], we sought to assess the biofilm-
inhibitory property of SPLUNC1 in the context of meningococcal 
colonization. We have shown that SPLUNC1 inhibits Nm biofilm 
formation and protects against adherence and subsequent inva-
sion into human 16HBE14 epithelial cells. We further identified 
a novel missense SPLUNC1 (p.G22E) mutation by WES of IMD 
patients, and demonstrated the relevance of SPLUNC1 in human 
meningococcal infection using in vitro assays.
Our results suggest that SPLUNC1 protects against Nm infec-
tion by inhibiting early biofilm formation. To understand how 
this antibiofilm effect relates to defense against Nm infection 
of human airway epithelial cells, we assessed Nm adherence 
and invasion into 16HBE14 epithelial cells using recombinant 
WT and mutant rSPLUNC1 proteins. Our data show that the 
presence of rSPLUNC1 results in marked reductions in Nm 
adherence and subsequent invasion into 16HBE14 cells. Our 
bacterial growth assays showed that rSPLUNC1 does not elicit 
a bactericidal effect on meningococcal growth, as we did not 
detect direct bacterial killing. Thus, the reductions we observed 
following Nm infection of the human 16HBE14 cells are un-
likely to be due to the reduced bacterial burden by direct bac-
terial killing, but rather resulted through the prevention of 
Nm biofilm formation or adherence and invasion into epithe-
lial cells. Our findings are consistent with a previous report on 
SPLUNC1’s surfactant activity on Gram-negative bacteria, in-
cluding Klebsiella pneumoniae, where SPLUNC1 was shown to 
inhibit bacterial biofilm formation on cultured human cells but 
had no direct bactericidal effect [27].
To address the question of whether our novel G22E mutation 
confers susceptibility to IMD, we characterized the mutation 
in the context of an Nm infection using rSPLUNC1 proteins. 
We demonstrated that the G22E mutant had an impaired ability 
to inhibit early Nm biofilm formation, compared with WT 
rSPLUNC1, when cultured on an abiotic surface. Consistent 
with this, we observed a significant increase in the number of 
Nm cells adhering to and invading human 16HBE14 cells in 
the presence of mutant G22E rSPLUNC1, compared with WT 
rSPLUNC1. Furthermore, as patient cells expressing the heter-
ozygous mutation were unavailable, the impact of the mutant 
protein on WT function was tested using the Nm adherence 
assay. The mutant G22E protein was found to function in a 
dominant negative manner from this assay [41, 42]. Our results 
suggest that the G22E mutation located in this functional do-
main may disrupt the normal function of SPLUNC1 through 
the modulation of its surfactant properties, including surface 
tension regulation on epithelial surfaces in a steady state and 
during infection. Furthermore, the impairment in antibiofilm 
activity is not caused by a deficiency in the LPS-binding ability 
of the G22E mutant, as it had normal LPS binding. These find-
ings support the proposal that the LPS-binding and antibiofilm 
activities of the protein are not functionally linked, and the cor-
responding domains do not necessarily overlap [42].
In conclusion, we have shown that SPLUNC1 plays an impor-
tant role in protection against Nm adherence and the subsequent 
invasion of respiratory epithelial cells. We further demonstrated 
that the novel G22E mutation identified in 3 IMD patients may 
confer a predisposition to IMD by impairing the protective role 
of SPLUNC1 against Nm infection. Taken together, these results 
build on earlier findings of the antimicrobial role that SPLUNC1 
plays in Gram-negative bacterial infections by preventing biofilm 
formation. We describe here a novel genetic aetiology of IMD in 
relation to the colonization and invasion of host epithelial bar-
riers by Nm, thereby increasing susceptibility to IMD. Identifying 
Figure 6. Both WT and mutant G22E rSPLUNC1 proteins bind LPS. Binding of Nm 
LPS or Salmonella Minnesota LPS are shown, with increasing doses of either WT 
or mutant G22E rSPLUNC1 proteins determined by ELISA. All experiments were 
performed 3 times and results are shown as means ± SDs. Abbreviations: ELISA, 
enzyme-linked immunosorbent assay; LPS, lipopolysaccharide; Nm, Neisseria 
meningitidis; OD, optical density; rSPLUNC1, recombinant SPLUNC1; SD, standard 
deviation; WT, wild-type. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz600/5526731 by guest on 06 February 2020
8 • cid 2019:XX (XX XXXX) • Mashbat et al
rare mutations that modulate the activity of SPLUNC1 will help 
unravel the functional domains of this multifunctional, innate 
immune defense protein and facilitate the identification of indi-
viduals who are at risk of developing invasive disease.
Supplementary Data
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Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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